Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 319,300 shares, an increase of 9.5% from the July 15th total of 291,500 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average trading volume of 68,900 shares, the short-interest ratio is currently 4.6 days.

Insider Transactions at Gyre Therapeutics

In other news, Director Nassim Usman sold 3,452 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the sale, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Rhumbline Advisers bought a new stake in Gyre Therapeutics during the second quarter worth $123,000. Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics in the second quarter worth $218,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $220,000. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Stock Performance

Shares of GYRE stock traded up $0.87 on Monday, hitting $11.76. The stock had a trading volume of 26,574 shares, compared to its average volume of 74,258. The business has a 50 day moving average of $12.13 and a 200 day moving average of $14.39. Gyre Therapeutics has a 12-month low of $4.80 and a 12-month high of $30.40.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.